Nephrol Dial Transplant (2002) 17: 923-926
© 2002 European Renal Association-European Dialysis and Transplant Association
Case Report
A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis
1 Department of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium, 2 Department of Clinical Chemistry, Georg-August-Universität, Göttingen, Germany and 3 Department of Clinical Immunology, University Hospital Gasthuisberg, Leuven, Belgium
Mycophenolate mofetil (MMF) is increasingly used for prevention of allograft rejection and to treat immune disorders. We report the development of an acute inflammatory syndrome in two patients with Wegener's granulomatosis after MMF was introduced, because of persistent renal and systemic disease activity despite cyclophosphamide treatment. Within 1 week both patients developed an acute inflammatory syndrome, characterized by fever, arthralgias and muscle pain. No infection could be detected and no indications for increased Wegener's activity were present. MMF was stopped resulting in a rapid and complete resolution of the syndrome. A rechallenge with 2 g of MMF in the second patient resulted in a relapse of the syndrome within 4 days. There was an association between symptoms and increased levels of mycophenolic acid (MPA) acyl glucuronide and serum interleukin-6, suggesting the induction of inflammatory cytokines by MPA acyl glucuronide as the cause of the syndrome. Therefore, special attention should be given to side effects such as fever, arthralgias and muscle pain when treating patients with Wegener's granulomatosis during the active phase. Because this side effect of MMF may also occur after solid organ transplantation and in other immune disorders, pharmacokinetic profiling of MPA and MPA acyl glucuronide is needed in future studies with MMF.
Keywords: cytokines; inflammatory syndrome; mycophenolate mofetil; Wegener's granulomatosis
Correspondence and offprint requests to: Bart Maes, Department of Nephrology, University Hospital Gasthuisberg, B-3000 Leuven, Belgium. Email: Bart.Maes{at}UZ.KULeuven.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. M. Davies, J. Grinyo, R. Heading, B. Maes, H.-U. Meier-Kriesche, and M. Oellerich Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2440 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bernard, J. Tojcic, K. Journault, L. Perusse, and C. Guillemette Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid Drug Metab. Dispos., September 1, 2006; 34(9): 1539 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Piccoli, M. Rossetti, C. Guarena, V. Consiglio, E. Mezza, G. Soragna, G. Grassi, M. Burdese, M. Gai, P. Marchetti, et al. Myalgia: an uncommon or underestimated side effect of mycophenolate mophetil after transplantation? Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1940 - 1942. [Full Text] [PDF]
|
|
|
|
|
|
M. Polenakovic, L. Grcevska, and S. Dzikova Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1233 - 1234. [Full Text] [PDF]
|
|